TransREAL
Research type
Research Study
Full title
TransREAL A translational sub-study of REAL2 and REAL3.
IRAS ID
263511
Contact name
David Cunningham
Contact email
Sponsor organisation
The Royal Marsden Hospital NHS Foundation Trust
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
The REAL2 and REAL3 trials investigated systemic chemotherapy in patients with advanced oesophagogastric cancer. The patient data sets from these large trials represent an unparalleled opportunity to investigate possible markers which can predict which patients benefit most from certain types of chemotherapy and to identify which patients have better survival. Similarly, identifying which patients don't benefit from certain treatments will spare them unnecessary side effects.
This study will profile the genetic landscape and image-based features of advanced oesophagogastric cancer samples from these two trials in order to identify these potential markers which correlate with response or resistance to platinum chemotherapy drugs and also survival.REC name
East of England - Cambridge South Research Ethics Committee
REC reference
19/EE/0261
Date of REC Opinion
25 Sep 2019
REC opinion
Further Information Favourable Opinion